Last reviewed · How we verify

Congenital hemolytic uremic syndrome — Treatment Landscape & Competitive Intelligence

Congenital hemolytic uremic syndrome (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Congenital hemolytic uremic syndrome, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
H5G1.1 ECULIZUMAB AstraZeneca Complement Inhibitor [EPC] C5 2007-01-01
Soliris Soliris Apellis Pharmaceuticals, Inc. Complement C5

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Apellis Pharmaceuticals, Inc. · 1 drug in Congenital hemolytic uremic syndrome
  2. AstraZeneca · 1 drug in Congenital hemolytic uremic syndrome

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Congenital hemolytic uremic syndrome:

Cite this brief

Drug Landscape (2026). Congenital hemolytic uremic syndrome — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/congenital-hemolytic-uremic-syndrome. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing